Promoted Content Promoted Content

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for NLS Pharmaceutics

    Client Virtual Booth

    NLS PHARMACEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    NLS Pharmaceutics
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    The Circle 6 | P.O. Box CH - 8058 Zurich
    Telephone
    Telephone
    +41 44 512 21 50
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nlspharma.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
    NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023

    https://www.accesswire.com/viewarticle.aspx?id=752824&lang=en

    ACCESSWIRE
    04 May 2023
    Share Share
    FDA approves NLS’ narcolepsy therapy Phase III programme
    FDA approves NLS’ narcolepsy therapy Phase III programme

    https://www.clinicaltrialsarena.com/news/fda-nls-narcolepsy-phase-iii/

    CLINICAL TRIALS ARENA
    03 May 2023
    Share Share
    NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)
    NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)

    https://www.accesswire.com/viewarticle.aspx?id=752432&lang=en

    BUSINESSWIRE
    02 May 2023
    Share Share
    NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society
    NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society

    https://www.accesswire.com/viewarticle.aspx?id=751094&lang=en

    ACCESSWIRE
    25 Apr 2023
    Share Share
    NLS Announces Label Extension Study Six-Month Data for Quilience Mazindol ER
    NLS Announces Label Extension Study Six-Month Data for Quilience Mazindol ER

    https://www.accesswire.com/viewarticle.aspx?id=745926&lang=en

    ACCESSWIRE
    27 Mar 2023
    Share Share
    NLS Pharmaceutics to Present at the 35th Annual Roth Conference
    NLS Pharmaceutics to Present at the 35th Annual Roth Conference

    https://www.accesswire.com/viewarticle.aspx?id=741403&lang=en

    ACCESSWIRE
    01 Mar 2023
    Share Share
    NLS Announces Completion of Extension Study with Quilience(R) (Mazindol ER)
    NLS Announces Completion of Extension Study with Quilience(R) (Mazindol ER)

    https://www.accesswire.com/737215/NLS-Pharmaceutics-Announces-Completion-of-Open-Label-Extension-Study-with-Quilience-Mazindol-ER-for-the-Treatment-of-Narcolepsy

    ACCESSWIRE
    30 Jan 2023
    Share Share
    NLS Pharma Regains Compliance with Nasdaq Stockholders' Equity Requirement
    NLS Pharma Regains Compliance with Nasdaq Stockholders' Equity Requirement

    https://www.accesswire.com/736677/NLS-Pharmaceutics-Regains-Compliance-with-Nasdaq-Stockholders-Equity-Requirement

    ACCESSWIRE
    26 Jan 2023
    Share Share
    NLS Pharmaceutics Announces Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
    NLS Pharmaceutics Announces Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity

    https://www.accesswire.com/736231/NLS-Pharmaceutics-Announces-New-In-Vitro-Data-Reconfirming-QuiliencesR-Mazindol-ER-Unique-Dual-Mechanism-of-Action-Involving-Significant-Orexin-2-Receptor-Activity

    ACCESSWIRE
    23 Jan 2023
    Share Share
    NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol
    NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol

    https://www.accesswire.com/732543/NLS-Pharmaceutics-Announces-Israeli-Patent-Grant-Covering-Mazindol-for-Treatment-of-Attention-Deficit-Hyperactivity-Disorder-and-Other-Sleep-Disorders-Through-2037

    ACCESSWIRE
    20 Dec 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2023-05-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search